In some instances, we partner our programs in order to accelerate timelines and better align resources.


We have a strategic collaboration with Mylan for the development and commercialization of revefenacin (TD-4208), our investigational LAMA in development for the treatment of chronic obstructive pulmonary disease (COPD). We are leading the Phase 3 U.S. development program and Mylan will be responsible for reimbursement of our costs for the program up until the approval of the first new drug application, after which costs will be shared. If a product developed under the collaboration is approved in the U.S., Mylan will lead commercialization and we will retain the right to co-promote the product in the U.S. under a profit-sharing arrangement. Outside the U.S. (excluding China), Mylan will be responsible for development and commercialization and will pay us a tiered royalty on net sales at percentage royalty rates ranging from low double-digits to mid-teens.


Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited has a global license, development and commercialization agreement for TD-8954, a selective 5-HT4 receptor agonist, for potential use in the treatment of gastrointestinal motility disorders, including short-term intravenous use for enteral feeding intolerance (EFI) to achieve early nutritional adequacy in critically ill patients at high nutritional risk, for which TD-8954 received U.S. Food and Drug Administration (FDA) Fast Track Designation.


We are partnered with Alfa Wassermann on the development and, subject to regulatory approval, commercialization of velusetrag (TD-5108), our investigational 5-HT4 agonist in development for gastrointestinal motility disorders. We are collaborating with Alfa Wassermann on the execution of a two-part Phase 2 program to test the efficacy, safety and tolerability of velusetrag in the treatment of patients with gastroparesis. Alfa Wassermann has an exclusive option to develop and commercialize velusetrag in the European Union, Russia, China, Mexico and certain other countries, while we retain full rights to velusetrag in the U.S., Canada, Japan and certain other countries.


We have a licensing agreement with Trek Therapeutics for an exclusive worldwide license for the development, manufacturing, use and commercial sale of our NS5A inhibitor, TD-6450, as a component in combination hepatitis C virus products.


We are partnered with SciClone Pharmaceuticals for the development and commercialization of VIBATIV® (telavancin) in China, as well as the Hong Kong SAR, the Macau SAR, Taiwan and Vietnam


We are partnered with R-Pharm on the development and, subject to regulatory approval, commercialization of two compounds -- TD-1792, our investigational glycopeptide-cephalosporin heterodimer antibiotic for the treatment of resistant Gram-positive infections, which has completed a Phase 2 proof-of-concept study; and VIBATIV® (telavancin), our lipoglycopeptide antibiotic. In both of the agreements, we granted R-Pharm exclusive development and commercialization rights in Russia, Ukraine, other member countries of the Commonwealth of Independent States, and Georgia.